Table 2

Twelve-month outcomes and medications by disease onset group compared using ANOVA

VariableAll patientsSimilar onset datePatient onset precedes MD datePatient onset after MD dateP value
DAS282.8 (1.4)2.8 (1.4)2.9 (1.4)2.7 (1.3)0.266
Change in DAS28 (0–12 months)−2.1 (1.8)−2.2 (1.8)−1.9 (1.7)−2.1 (1.5)0.016
Proportion in DAS28 remission (baseline)184 (7.3)125 (6.8)46 (9.8)13 (5.6)0.049
Proportion in DAS28 remission (12 months)847 (53.3)624 (54.1)138 (48.6)85 (55.6)0.207
CDAI8.2 (9.2)8.0 (9.0)9.2 (9.7)8.0 (9.8)0.109
Change in CDAI (0–12 months)−17.3 (15.3)−17.8 (15.6)−15.6 (15.0)−17.0 (13.8)0.070
Proportion in CDAI remission (baseline)36 (1.4)26 (1.4)9 (1.8)1 (0.4)0.316
Proportion in CDAI remission (12 months)575 (32.7)432 (34.0)88 (27.5)55 (32.7)0.083
SDAI8.9 (9.6)8.6 (9.4)9.9 (9.9)8.8 (10.2)0.136
Change in SDAI (0–12 months)−18.3 (16.4)−18.8 (16.7)−16.8 (16.0)−17.1 (14.2)0.168
Proportion in SDAI remission (baseline)38 (1.6)25 (1.4)11 (2.5)2 (0.9)0.204
Proportion in SDAI remission (12 months)509 (34.3)389 (36.2)76 (28.4)44 (31.9)0.045
HAQ-DI (0–3)0.5 (0.6)0.5 (0.6)0.6 (0.6)0.5 (0.7)0.048
Change in HAQ-DI (0–12 months)−0.5 (0.7)−0.5 (0.7)−0.4 (0.7)−0.5 (0.7)0.001
Erosions (%)323 (17.1)237 (17.3)59 (17.3)27 (15.1)0.763
Swollen joint count (0–28)2 (3)2 (3)2 (3)2 (4)0.558
Tender joint count (0–28)2 (4)2 (4)2 (4)2 (4)0.886
ESR15.4 (15.5)15.1 (15.5)16.4 (16.1)15.1 (13.5)0.501
CRP5.5 (9.5)5.3 (9.7)5.9 (9.6)5.7 (7.7)0.683
MD global assessment (0–10)1.4 (1.9)1.4 (1.9)1.6 (2.0)1.4 (2.0)0.092
Patient global score (0–10)2.9 (2.7)2.8 (2.7)3.3 (2.7)2.8 (2.6)0.028
Oral corticosteroid (%)283 (10)201 (10)54 (11)28 (11)0.858
Parenteral corticosteroid (%)211 (8)157 (8)36 (7)18 (7)0.777
RA therapy
MTX monotherapy422 (16)302 (16)77 (16)43 (18)0.731
MTX combination953 (36)721 (37)148 (30)84 (34)0.008
Other DMARDs352 (13)253 (13)70 (14)29 (12)0.671
Biologics265 (10)193 (10)50 (10)22 (9)0.873
None of the above691 (26)471 (24)152 (30)68 (28)0.013
  • Remission: DAS28≤2.6, CDAI≤2.8, SDAI≤3.3; results are in mean (SD) if not specified otherwise.

  • Statistically significant values are indicated in bold.

  • ANOVA, analysis of variance; CDAI, Clinical Disease Activity Index; CRP, C reactive protein; DAS28, Disease Activity Score based on 28 joint count; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; MD, medical doctor; MTX, methotrexate; SDAI, Simplified Disease Activity Index.